EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Determining the Quality of Functional Evidence for Coding Variants in CYP1B1 for Use in Variant Classification

Kathryn P Burdon iD, Johanna Hadler iD, Patricia Graham iD, Stuart W Tompson iD, Francesca Pasutto iD, Kristina Whisenhunt iD, Owen Siggs iD, Subhabrata Chakrabarti iD, Terri L Young iD, David A Mackey iD, Andrew Dubowsky iD, Emmanuelle Souzeau iD

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/6767909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 08.11.2026. Verfasst von Kathryn P Burdon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Menzies Institute for Medical Research University of Tasmania Hobart Tasmania Australia utas.edu.au. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1B1, Genetic Variation, Glaucoma, Open Reading Frames. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Health and Medical Research Council, Stan Perron Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biallelic variants in the CYP1B1 gene are associated with primary congenital glaucoma and some instances of anterior segment dysgenesis and juvenile open‐angle glaucoma. Genetic testing is increasingly used in the diagnosis of these conditions and to inform future family planning decisions. Variant‐specific functional data play a critical role in variant classification during the interpretation of genetic test results. In this study, the ClinGen Glaucoma Variant Curation Expert Panel (VCEP) evaluated published functional assays assessing CYP1B1 protein stability and enzymatic activity to determine which assays meet the recommended standards for use in variant classification, specifically when applying the PS3 or BS3 criteria from the ACMG/AMP variant interpretation guidelines. Following a comprehensive literature review, the panel identified assays that examined protein abundance and stability, as well as enzymatic activity across a range of substrates. The VCEP determined that BS3 (benign functional evidence) should not be applied to CYP1B1 as variants exhibit substrate‐specific effects. After detailed review, the panel determined that two assays had an adequate number of validation controls and could distinguish between pathogenic and benign variants. The first measured 17 β ‐estradiol activity using a commercially available luminescence kit in yeast microsomes. The second assessed benzo[a]pyrene activity via HPLC detection, also in yeast microsomes. A consensus review of additional assays recommends the inclusion of more clinical controls to either establish a significant OddsPath or to better define thresholds for applying pathogenic evidence. Incorporating validated functional data into the curation of CYP1B1 variants will enhance the accuracy of variant classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP1B1Genetic VariationGlaucomaOpen Reading FramesHumansMutationGenetic Testing

Substanzen

Cytochrome P-450 CYP1B1CYP1B1 protein, human

Autor:innen und Institutionen

  • Menzies Institute for Medical Research University of Tasmania Hobart Tasmania Australia utas.edu.au.
  • Department of Ophthalmology Flinders Health and Medical Research Institute Flinders University Adelaide South Australia Australia flinders.edu.au.
  • Department of Ophthalmology and Visual Sciences University of Wisconsin-Madison Madison Wisconsin USA wisc.edu.
  • Institute of Human Genetics Friedrich-Alexander-Universitätsklinikum Erlangen-Nürnberg Erlangen Germany geneticcentre.org.
  • Garvan Institute of Medical Research Sydney Australia garvan.org.au.
  • Brien Holden Eye Research Centre L. V. Prasad Eye Institute Hyderabad India lvpei.org.

ORCID-Profile: Kathryn P Burdon, Johanna Hadler, Patricia Graham, Stuart W Tompson, Francesca Pasutto, Kristina Whisenhunt, Owen Siggs, Subhabrata Chakrabarti, Terri L Young, David A Mackey, Andrew Dubowsky, Emmanuelle Souzeau

Förderung

  • NEI NIH HHS
  • National Health and Medical Research Council
  • Stan Perron Charitable Foundation
  • Research to Prevent Blindness
  • Flinders University

Zitieren

APA

Burdon, K. P., Hadler, J., Graham, P., Tompson, S. W., Pasutto, F., Whisenhunt, K., Siggs, O., Chakrabarti, S., Young, T. L., Mackey, D. A., Dubowsky, A., & Souzeau, E. (2026). Determining the Quality of Functional Evidence for Coding Variants in CYP1B1 for Use in Variant Classification. Human Mutation, 2026(1). https://doi.org/10.1155/humu/6767909

Vancouver

Burdon KP, Hadler J, Graham P, Tompson SW, Pasutto F, Whisenhunt K, et al. Determining the Quality of Functional Evidence for Coding Variants in CYP1B1 for Use in Variant Classification. Human Mutation. 2026;2026(1). doi:10.1155/humu/6767909

BibTeX
@article{Burdon2026,
  author = {Burdon, Kathryn P and Hadler, Johanna and Graham, Patricia and Tompson, Stuart W and Pasutto, Francesca and Whisenhunt, Kristina and Siggs, Owen and Chakrabarti, Subhabrata and Young, Terri L and Mackey, David A and Dubowsky, Andrew and Souzeau, Emmanuelle},
  title = {Determining the Quality of Functional Evidence for Coding Variants in CYP1B1 for Use in Variant Classification},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/6767909}
}
Kostenlos starten →